Ariad Staffs Up In Anticipation of Growth
Malorye Allison11/27/07
Cambridge, MA-based Ariad Pharmaceuticals (NASDAQ: ARIA) has made three key new appointments in anticipation of the launch of its first product and the growth of its pipeline. Matthew E. Ros is vice president, oncology marketing, Virginia R. Dean is vice president, human resources, and Frank G. Haluska is senior medical director. Ariad’s deforolimus is in Phase 3 trials for bone tumors and Phase 2 for several other types of cancer. This summer Ariad inked a deal worth potentially $1B with Merck around this targeted cancer drug.
